OPKO Health (OPK) said Monday it will work with Entera Bio (ENTX) to push an oral dual agonist for obesity and related conditions into clinical testing.
The drug combines OPKO's extended-release GLP-1/glucagon analog with Entera's tablet formulation technology, with an FDA filing planned later this year, OPKO said.
Under the agreement, OPKO will cover 60% of development expenses and Entera 40%, with ownership split along the same lines, the companies said.
To help cover its share, Entera said it sold roughly 3.7 million shares to OPKO for $2.17 each. If Entera decides to drop out, it will still retain a 15% stake.
Entera's shares were up more than 10% in recent Monday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。